SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst 1995;87: 796802.
  • 2
    Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189: 129.
  • 3
    Ho GY, Buck RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87: 136571.
  • 4
    Rozendaal L, Walboomers JMM, Van der Linden JC. High risk human papillomavirus in cytomorphological normal smears has a high predictive value for development of severe dysplasia. Int J Cancer 1996;68: 7669.
  • 5
    Spitzer M. 1999. Lower genital tract intraepithelial neoplasia in HIV-infected women: guidelines for evaluation and management. Obstet Gynecol Surv 1999;54: 1317.
  • 6
    Ho GY, Burk RD, Fleming I, et al. Risk of genital human papillomavirus infection in women with human immunodeficiency virus-induced immunosuppression. Int J Cancer 1994;56: 78892.
  • 7
    Petry KW, Scheffel D, Bode U, et al. Cellular immunodeficiency enhances the progression of human papillomavirus-associated cervical lesions. Int J Cancer 1994;57: 83640.
  • 8
    Muller M, Viscidi RP, Sun Y, et al. 1992. Antibodies to HPV 16 E6 and E7 proteins as markers for HPV 16 associated invasive cancer. Virology 1992;187: 50814.
  • 9
    de Gruijl TD, Bontkes HJ, Stukart MJ, et al. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. J Natl Cancer Inst 1997;89: 6308.
  • 10
    Rocha-Zavaleta L, Jordan D, Pepper S, et al. Differences in serological IgA responses to recombinant baculovirus-derived human papillomavirus E2 protein in the natural history of cervical neoplasia. Br J Cancer 1997;75: 114450.
  • 11
    Man S. Human cellular immune responses against human papillomaviruses in cervical neoplasia. In: Expert reviews in molecular medicine; 1998. Accession number txt001smc. ISSN1462-3974.
  • 12
    Halbert CL, Demers GW, Galloway DA. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol 1991;65: 4738.
  • 13
    von Knebel Doeberitz M, Rittmuller C, zur Hausen H, et al. 1992. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. Int J Cancer 1992;51: 8314.
  • 14
    Benson JD, Howley PM. Amino-terminal domains of the bovine papillomavirus type 1 E1 and E2 proteins participate in complex formation. J Virol 1995;69: 436472.
  • 15
    Androphy EJ, Lowy DR, Schiller JT. Bovine papillomavirus E2 trans-activating gene product binds to specific sites in papillomavirus DNA. Nature 1987;325(6099): 703.
  • 16
    Giri I, Yaniv M. Structural and mutational analysis of E2 trans-activating proteins of papillomaviruses reveals three distinct functional domains. EMBO J 1988;7: 28239.
  • 17
    Stubenrauch F, Colbert AM, Laimins LA. Transactivation by the E2 protein of oncogenic human papillomavirus type 31 is not essential for early and late viral functions. J Virol 1998;72: 811523.
  • 18
    Sedman J, Stenlund A. Co-operative interaction between the initiator E1 and the transcriptional activator E2 is required for replicator specific DNA replication of bovine papillomavirus in vivo and in vitro. EMBO J 1995;14: 621828.
  • 19
    McBride AA, Romanczuk H, Howley PM. The papillomavirus E2 regulatory proteins. J Biol Chem 1991;266: 184114.
  • 20
    Stevenson M, Hudson LC, Burns JE, et al. Inverse relationship between the expression of the human papillomavirus type 16 transcription factor E2 and virus DNA copy number during the progression of cervical intraepithelial neoplasia. J Gen Virol 2000; 81(Pt 7): 182532.
  • 21
    Han R, Cladel NM, Reed CA, et al. DNA vaccination prevents and/or delays carcinoma development of papillomavirus-induced skin papillomas on rabbits. J Virol 2000;74: 97126.
  • 22
    Han R, Reed CA, Cladel NM, et al. Immunization of rabbits with cottontail rabbit papillomavirus E1 and E2 genes: protective immunity induced by gene gun-mediated intracutaneous delivery but not by intramuscular injection. Vaccine 2000;18: 293744.
  • 23
    Schiller JT, Hidesheim A. 2000. Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report. J Clin Virol 2000;19: 6774.
  • 24
    Graham DA, Herrington CS. 2000. HPV-16 E2 gene disruption and sequence variation in CIN 3 lesions and invasive squamous cell carcinomas of the cervix: relation to numerical chromosome abnormalities. Mol Pathol 2000;53: 2016.
  • 25
    Lehtinen M, Hibma MH, Stellato G, et al. Human T cell epitopes overlap B cell and putative cytotoxic T cell epitopes in the E2 protein of human papillomavirus type 16. Biochem Biophys Res Commun 1995;209: 541-546.
  • 26
    Bontkes HJ, de Gruijl TD, Bijl A, Verheijen RH, Meijer CJ, Scheper RJ, et al. Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia. J Gen Virol 1999;80(Pt 9): 24539.
  • 27
    Konya J, Eklund C, AfGeijersstam V, et al. Identification of a cytotoxic T-lymphocyte epitope in the human papillomavirus type 16 E2 protein. J Gen Virol 1997;78: 261520.
  • 28
    Shimonkevitz R, Kappler J, Marrack P, et al. 1983. Antigen recognition by H-2-restricted T cells. I. Cell-free antigen processing. J Exp Med 1983;158: 30316.
  • 29
    McDevitt HO, Tyan ML. Genetic control of the antibody response in inbred mice. Transfer of response by spleen cells and linkage to the major histocompatibility (H-2) locus. J Exp Med 1968;128: 111.
  • 30
    Austyn J. Dendritic cells. Curr Opin Hematol 1998;5: 315.
  • 31
    Webster K, Parish J, Pandya M, et al. 2000. The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway. J Biol Chem 2000;275: 8794.
  • 32
    Schmittel A, Keilholz U, Scheibenbogen C. Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J Immunol Methods 1997;210: 16774.
  • 33
    Agger R, Crowley MT, Witmer Pack MD. The surface of dendritic cells in the mouse as studied with monoclonal antibodies. Int Rev Immunol 1990;6: 89101.
  • 34
    Mayordomo JL, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumour vaccines. Stem Cells 1997;15: 94103.
  • 35
    Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9: 27196.
  • 36
    de Wynter EA, Buck D, Hart C, et al. CD34+AC133+ cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors. Stem Cells 1998;16: 38796.
  • 37
    Lalvani A, Brookes R, Hambleton S, et al. Rapid effector function in CD8+ memory T cells. J Exp Med 1997;186: 85965.
  • 38
    McCutcheon M, Wehner N, Wensky A, et al. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes. J Immunol Methods 1997;210: 14966.
  • 39
    Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401(6754): 70812.
  • 40
    Melkert PJW, Hopman E, van den Brule AJC, et al. 1993. Prevalence of HPV in cytomorphologically normal smears as determined by the polymerase chain reaction is age-dependent. Int J Cancer 1993;53: 91923.
  • 41
    Walboomers JMM, Jacobs MV, van Oostveen JW, et al. Detection of human papillomavirus infections and possible clinical implications. In: GrossG, von KroghG, eds. Human papillomavirus infections in dermatovenereology. New York: CRC Press, 1997. 34164.
  • 42
    Schiffman MH. Epidemiology of cervical human papillomavirus infections. In: Zur HausenH, ed. Human pathogenic papillomaviruses. Current topics in microbiology and immunology. Berlin: Springer Verlag, 1994. 5581.
  • 43
    Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338: 4238.
  • 44
    van der Burg SH, Ressing ME, Kwappenberg KMC, et al. 2001. Natural T-helper immunity against human papillomavirus type 16 (HPV 16) E7-derived peptide epitopes in patients with HPV 16 positive cervical lesions: identification of three human leukocyte antigen class II restricted epitopes. Int J Cancer 2001;91: 6128.
  • 45
    Zinkernagel RM. Immunology taught by viruses. Science 1996; 271: 1738.